GlassScriptPhysician profile
Santiago M Thibaud
NPI 1861888943
$854.20
in general payments reported to CMS, 2019-2025
10 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.47 · 2023: $300 · 2024: $111 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $191.23 | 2023-2025 | Ninlaro |
| Celgene Corporation | $166.08 | 2023-2025 | Pomalyst |
| Janssen Research & Development, LLC | $129.70 | 2023 | |
| Janssen Biotech, INC. | $120.99 | 2023-2025 | Carvykti, Tecvayli, Darzalex |
| Genzyme Corporation | $72.07 | 2022 | |
| Adaptive Biotechnologies Corporation | $49.48 | 2025 | Clonoseq |
| Karyopharm Therapeutics INC. | $46.90 | 2022-2023 | Xpovio |
| Pfizer INC. | $27.57 | 2025 | |
| Janssen Scientific Affairs, LLC | $27.34 | 2024 | Imbruvica, Darzalex, Carvykti |
| Abbvie INC. | $22.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santiago Thibaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.